In an international first, people with lung cancer will find out if a
new combination of drugs can kick-start their bodies' ability to fight
back against the disease. They'll be part of a clinical trial now
enrolling participants at the Medical University of South Carolina.(MUSC)
The trial will focus on people with non-small cell lung cancer,
the most common type. Medical oncologist John Wrangle, M.D., will serve
as principal investigator on the three-year project. Mark Rubinstein,
Ph.D., worked with him to design the trial. Rubinstein said the research will test the effectiveness of using the
checkpoint inhibitor nivolumab with the immune stimulation drug ALT-803.
"Instead of simply cutting the brake cables of the immune cells using
only a checkpoint blocker, we are also adding fuel in the form of
ALT-803 so the immune cells will have optimal stimulation and ability to
kill tumor cells."
The trial's formal name is a Phase IB/II Study of ALT-803 plus
nivolumab in patients with pretreated, advanced or metastatic non-small
cell lung cancer. To ask about enrolling, call Amanda Gilbert at
843-792-8795.
No comments:
Post a Comment